We developed a nanotechnology based-cell mediated drug delivery system by loading myelin antigen-specific T cells with nanoparticles bound to anti-CD20 monoclonal antibody. Anti-CD20 antibody is a current treatment (ocrelizumab) for multiple sclerosis (MS), a chronic, inflammatory and autoimmune disease of the central nervous system (CNS). CD20-depletion has been associated with efficacy in active relapsing and progressive MS, but may not efficiently target inflammatory cells compartmentalized in the CNS. In our work, the intravenous transfer of T cells containing nanoparticle-anti-CD20 complex in mice causes B-cell depletion in the spleen and in the brain, whereas the injection of anti-CD20 alone depletes B cells only in the spleen. Testing this system in Experimental Autoimmune Encephalomyelitis (EAE), animal model of MS, we found that spinal cord B-cell depletion ameliorates the disease course and pathology.
T-cell delivery of nanoparticles-bound anti-CD20 monoclonal antibody: successful B-cell depletion in the spinal cord during Experimental Autoimmune Encephalomyelitis / Alberto Carnasciali, PharmD; Roberta Amoriello, PhD; Elena Bonechi, PhD; Alessio Mazzoni, PhD; Costanza Ravagli, PhD; Saer Doumett, PhD; Laura Cappiello, MSc; Mario Milco D'Elios, MD; Giovanni Baldi, PhD; Clara Ballerini. - In: JOURNAL OF NEUROIMMUNE PHARMACOLOGY. - ISSN 1557-1904. - ELETTRONICO. - (2020), pp. 1-14. [10.1007/s11481-020-09931-w]
T-cell delivery of nanoparticles-bound anti-CD20 monoclonal antibody: successful B-cell depletion in the spinal cord during Experimental Autoimmune Encephalomyelitis
Clara Ballerini
2020
Abstract
We developed a nanotechnology based-cell mediated drug delivery system by loading myelin antigen-specific T cells with nanoparticles bound to anti-CD20 monoclonal antibody. Anti-CD20 antibody is a current treatment (ocrelizumab) for multiple sclerosis (MS), a chronic, inflammatory and autoimmune disease of the central nervous system (CNS). CD20-depletion has been associated with efficacy in active relapsing and progressive MS, but may not efficiently target inflammatory cells compartmentalized in the CNS. In our work, the intravenous transfer of T cells containing nanoparticle-anti-CD20 complex in mice causes B-cell depletion in the spleen and in the brain, whereas the injection of anti-CD20 alone depletes B cells only in the spleen. Testing this system in Experimental Autoimmune Encephalomyelitis (EAE), animal model of MS, we found that spinal cord B-cell depletion ameliorates the disease course and pathology.File | Dimensione | Formato | |
---|---|---|---|
JNIP 2020.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
9.59 MB
Formato
Adobe PDF
|
9.59 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.